Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

JACC. Heart failure - 1 Dec 2014

McNamara Dennis M, Taylor Anne L, Tam S William, Worcel Manuel, Yancy Clyde W, Hanley-Yanez Karen, Cohn Jay N, Feldman Arthur M

Abstract excerpt

OBJECTIVES: The purpose of this study was to evaluate the influence of the guanine nucleotide-binding proteins (G-proteins), beta-3 subunit (GNB3) genotype on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in A-HeFT (African American Heart Failure Trial). BACKGROUND: GNB3 plays a role in alpha2-adrenergic signaling. A polymorphism (C825T) exists, and the T allele...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Heterotrimeric GTP-Binding Proteins

Share to Length of Stay

Share to Quality of Life

Share to Vasodilator Agents

Share to Ventricular Dysfunction, Left

Source

Identifiers

PMID: 25306451
DOI: 10.1016/j.jchf.2014.04.016

Genes

GNB3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.PMID 25306451Read ↗

Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.Semantic proximity Read ↗

Racial differences in heart failure therapeutics.Semantic proximity Read ↗

β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant.Semantic proximity Read ↗

GNAS gene variants affect β-blocker-related survival after coronary artery bypass grafting.Semantic proximity Read ↗

Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.Semantic proximity Read ↗

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized TrialsSemantic proximity Read ↗

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy.Semantic proximity Read ↗

Association between Adrenergic Receptor Genotypes and Beta-Blocker Dose in Heart Failure Patients: Analysis from the HF-ACTION DNA SubstudySemantic proximity Read ↗

Emerging role of pharmacogenomics in heart failure.Semantic proximity Read ↗

G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.